Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: human hepatocytes Clear all
Recruiting Phase 1 Interventional

Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B

NCT06680232
View directory record Official record
Conditions
HEPATITIS B CHRONIC
Interventions
PBGENE-HBV
Biological
Lead sponsor
Precision BioSciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

NCT04909450
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
CSB-001 Ophthalmic Solution 0.1%, Vehicle Control
Biological
Lead sponsor
Claris Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
45
States / cities
Cave Creek, Arizona • Loma Linda, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 30, 2026, 10:23 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers

NCT04781322
View directory record Official record
Conditions
Alcohol Associated Liver Disease, Heavy Drinking Behavior
Interventions
Alirocumab, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 30, 2026, 10:23 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

NCT06257355
View directory record Official record
Conditions
Corneal Scar
Interventions
CSB-001 Ophthalmic Solution 0.1%
Biological
Lead sponsor
Claris Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Loma Linda, California • Carmel, Indiana • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 30, 2026, 10:23 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Hepatocyte Transplantation in Liver Failure

NCT00805610
View directory record Official record
Conditions
Liver Failure
Interventions
Hepatocyte Transplantation
Biological
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 30, 2026, 10:23 AM EDT
Withdrawn Phase 1 Interventional

Hepatocyte Transplantation for Acute Decompensated Liver Failure

NCT01345565
View directory record Official record
Conditions
Liver Failure Acute
Interventions
human hepatocytes
Drug
Lead sponsor
Ira Fox
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 30, 2026, 10:23 AM EDT
Terminated Phase 2 Interventional

Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders

NCT01195753
View directory record Official record
Conditions
Urea Cycle Disorders
Interventions
HHLivC
Biological
Lead sponsor
Cytonet GmbH & Co. KG
Industry
Eligibility
1 Day to 5 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 30, 2026, 10:23 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

NCT06452316
View directory record Official record
Conditions
Limbal Stem Cell Deficiency
Interventions
CSB-001 Ophthalmic Solution 0.1%
Biological
Lead sponsor
Claris Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Loma Linda, California • Carmel, Indiana • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 30, 2026, 10:23 AM EDT
Terminated Phase 1 Interventional

Hepatocyte Transplantation for Liver Based Metabolic Disorders

NCT01345578
View directory record Official record
Conditions
Metabolic Diseases
Interventions
human hepatocyte transplantation, Preparative Radiation Therapy
Drug · Radiation
Lead sponsor
Ira Fox
Other
Eligibility
Up to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Oct 30, 2026, 10:23 AM EDT
Terminated Phase 3 Interventional Results available

Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD

NCT02612428
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
ELAD System, Standard of Care (Control)
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Little Rock, Arkansas • Coronado, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 30, 2026, 10:23 AM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial

NCT04087941
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
VM-202
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 30, 2026, 10:23 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Resveratrol and Human Hepatocyte Function in Cancer

NCT02261844
View directory record Official record
Conditions
Liver Cancer
Interventions
Resveratrol, Placebo
Dietary Supplement · Drug
Lead sponsor
University of Louisville
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 30, 2026, 10:23 AM EDT
Terminated Phase 3 Interventional

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT01697072
View directory record Official record
Conditions
Gastric Cancer
Interventions
Rilotumumab, Placebo, Epirubicin, Cisplatin, Capecitabine
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
16
States / cities
Tucson, Arizona • Aurora, Colorado • Pueblo, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

NCT03588299
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY2599023 (DTX201)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Little Rock, Arkansas • Ann Arbor, Michigan • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 30, 2026, 10:23 AM EDT